Understanding US FDA QSR, QMSR and ISO 13485 alignment
A Practical Guide for Medical Device Manufacturers
In the medical device industry, maintaining a robust Quality Management System (QMS) is not merely a regulatory requirement; it is fundamental to ensuring patient safety, product quality, and regulatory compliance.
Manufacturers are often required to navigate multiple standards and regulations, including ISO 13485 and the US FDA’s 21 CFR Part 820, which is transitioning from the Quality System Regulation (QSR) to the Quality Management System Regulation (QMSR). Understanding how these frameworks align—and where they differ—is essential for medical device companies operating in global markets.
What is FDA QSR?
QSR (Quality System Regulation) is the US FDA’s traditional framework for medical device quality, established under 21 CFR Part 820, to ensure that medical device manufacturers consistently design, produce and monitor medical devices that meet applicable safety and effectiveness requirements.
What is FDA QMSR?
QMSR (Quality Management System Regulation) is the amended FDA regulation under 21 CFR Part 820 that will take effect on 02 February 2026, transitioning the FDA’s Quality System Regulation to a framework that incorporates ISO 13485:2016 by reference. QMSR aligns FDA quality system requirements with international standards while retaining FDA-specific regulatory provisions.
What is ISO 13485 ?
ISO 13485:2016 is the international standard for medical device quality management systems. Unlike FDA regulations, it is standard-driven rather than regulation-driven and focuses on establishing consistent processes for designing, producing, and delivering medical devices that meet applicable safety and performance requirements. ISO 13485:2016 emphasizes risk management, process consistency, and traceability throughout the product lifecycle.
Key changes introduced by QMSR
With the transition to the Quality Management System Regulation (QMSR), US FDA has amended 21 CFR Part 820 to incorporate ISO 13485:2016 by reference. Key differences from the former QSR include:
| QMSR – Section | Removed & marked as reserved | New requirement aligning ISO 13485:2016 |
|---|---|---|
| Design Controls (§820.30) | Former design control requirements under §820.30 are removed and marked as reserved. | Design and development activities are now governed by ISO 13485:2016,Clause 7.3, as required under §820.10. |
| Document and Record Controls (§820.40, §820.180) | QSR-specific document and record control sections are removed and reserved. | Documentation and record retention requirements are now addressed through ISO 13485, Clause 4.2, with FDA-specific record content and accessibility requirements retainedunder §820.35. |
| Corrective and Preventive Action (CAPA) (§820.100) | The prescriptive CAPA requirements in §820.100 are removed and reserved. | Corrective action processes are now implemented in accordance with ISO 13485, Clauses 8.5.2 and 8.5.3, with FDA continuing to assess the effectiveness of corrective actions during inspections. |
| Purchasing Controls (§820.50) | Purchasing control requirements under §820.50 are removed and reserved. | Supplier evaluation, selection, and monitoring activities are now governed by ISO 13485, Clause 7.4. |
| Production and Process Controls (§820.70) | Production and process control requirements under §820.70 are removed and reserved. | Controls over manufacturing, process validation, and service provision are now addressed through ISO 13485, Clauses 7.5.1 and 7.5.6. |
Structure and approach
QMSR adopts the ISO 13485 Clause 4–8 structure, shifting FDA oversight from prescriptive regulatory sections to a standards-based quality management system framework.
Retention of FDA-specific requirements
While ISO 13485 forms the core of the quality system requirements, FDA-specific regulatory obligations—such as Medical Device Reporting (21 CFR Part 803), Unique Device Identification (21 CFR Part 830), corrections and removals (21 CFR Part 806), and traceability (21 CFR Part 821)—remain fully applicable.
Here are 6 steps for QMSR Compliance for Medtech manufacturers, this approach would help plan & execute QMSR updates applicable for QSR based Quality Management System!
This workflow outlines a practical approach for manufacturers transitioning to the FDA’s Quality Management System Regulation (QMSR).
- Step 1: Perform a QMSR-focused gap analysis
Conduct a gap analysis against ISO 13485:2016 as incorporated by reference under 21 CFR Part 820 (§820.10). Identify gaps in areas such as risk management, design and development controls, supplier controls, and corrective action processes.
Step 2: Map existing processes to ISO 13485 and FDA requirements
Map current quality system processes to ISO 13485 Clauses 4–8, and confirm alignment with FDA supplemental requirements, including Medical Device Reporting (21 CFR Part 803), corrections and removals (21 CFR Part 806), traceability (21 CFR Part 821), and Unique Device Identification (21 CFR Part 830).
- Step 3: Update documentation and terminology
Revise quality system documentation to reflect ISO 13485-aligned structure and terminology, while ensuring FDA-specific record and labelling requirements under Part 820 (e.g. §820.35 and §820.45) are clearly addressed.
- Step 4: Train personnel on QMSR expectations
Train relevant personnel on ISO 13485 requirements as enforced under QMSR, with particular focus on how FDA inspections will assess compliance through ISO-based processes and FDA regulatory outcomes.
- Step 5: Prepare for FDA and third-party audits
Ensure audit readiness by demonstrating consistent, harmonized processes that satisfy both ISO 13485 certification audits and FDA inspections under QMSR, supported by objective evidence and effective record control.
- Step 6: Drive continuous improvement
Use management review, internal audits, and corrective action processes to support continual improvement of the quality management system, reinforcing product safety, effectiveness, and regulatory compliance.
In conclusion, as the FDA transitions to the Quality Management System Regulation (QMSR), alignment with ISO 13485:2016 provides medical device manufacturers with a practical opportunity to simplify compliance, strengthen risk management and support regulatory activities in US and global markets. Organizations that proactively harmonize their quality management systems will be better positioned for FDA inspections, ISO certification audits and sustained international market access while maintaining product quality and patient safety.
At RegTrac, we help medical device manufacturers navigate QMSR and ISO 13485 compliance with confidence. From gap assessments and process alignment to audit readiness and risk management support, our experts ensure your quality systems are robust and globally aligned.
Ready to simplify compliance and strengthen your QMS? Book a meeting today and discuss how RegTrac can support your regulatory journey.
Informative Blogs
Our Services
Cosmetics
Medical Devices
Ready to take the next step? Let’s connect and explore how RegTrac can elevate your compliance journey!